Three-Month Clofazimine Regimen Fails to Shorten Tuberculosis Treatment
A 3-month clofazimine- and rifapentine-containing regimen for drug-susceptible TB failed to improve cure rates and caused more severe adverse events than standard therapy, according to the Clo-Fast trial.